Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers
Awakn Designates Program AWKN-002 for Alcohol Use Disorders in the US MarketToronto, Ontario--(Newsfile Corp. - January 24, 2024) - Awakn...